Kaleido Biosciences Ownership

KLDO -  USA Stock  

USD 5.69  0.03  0.52%

Some institutional investors establish a significant position in stocks such as Kaleido Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Kaleido Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please see Stocks Correlation.

Search Ownership Allocation 

Kaleido Biosciences Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.66. Current Ratio is expected to rise to 4.08 this year, although the value of Earnings per Basic Share will most likely fall to (2.63) .
Kaleido Biosciences maintains a total of fourty-two million five hundred twenty thousand outstanding shares. The majority of Kaleido Biosciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kaleido Biosciences to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kaleido Biosciences. Please pay attention to any change in the institutional holdings of Kaleido Biosciences as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Kaleido Stock Ownership Analysis

About 81.0% of the company shares are owned by institutional investors. The book value of Kaleido Biosciences was now reported as 1.69. The company recorded a loss per share of 2.38. Kaleido Biosciences had not issued any dividends in recent years. Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. To find out more about Kaleido Biosciences contact Mike Bonney at 617 674 9000 or learn more at http://kaleido.com.
Besides selling stocks to institutional investors, Kaleido Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Kaleido Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Kaleido Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Kaleido Biosciences Quarterly Share Based Compensation

2.38 MillionShare
Roughly 4.0% of Kaleido Biosciences are currently held by insiders. Unlike Kaleido Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Kaleido Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Kaleido Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kaleido Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kaleido Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kaleido Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of September 2021
Other Events
11th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of July 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
16th of February 2021
Unclassified Corporate Event

Kaleido Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kaleido Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kaleido Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kaleido Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Hylckama Vlieg Johan over three weeks ago via Macroaxis 
Acquisition by Van Hylckama Vlieg Johan of 40000 shares of Kaleido Biosciences subject to Rule 16b-3
Prener Anne over two months ago via Macroaxis 
Acquisition by Prener Anne of 15000 shares of Kaleido Biosciences subject to Rule 16b-3
Van Hylckama Vlieg Johan over three months ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Jerald Korn over six months ago via Macroaxis 
Acquisition by Jerald Korn of 60000 shares of Kaleido Biosciences subject to Rule 16b-3
Menichella Daniel L over six months ago via Macroaxis 
Purchase by Menichella Daniel L of 20000 shares of Kaleido Biosciences
Flagship Ventures Fund Iv General Partner Llc over six months ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Jerald Korn over six months ago via Macroaxis 
Acquisition by Jerald Korn of 45000 shares of Kaleido Biosciences subject to Rule 16b-3
Prener Anne over a year ago via Macroaxis 
Acquisition by Prener Anne of 15000 shares of Kaleido Biosciences subject to Rule 16b-3
Nutritional Health Ltp Fund General Partner Llc over a year ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Melas Kyriazi Theo over a year ago via Macroaxis 
Purchase by Melas Kyriazi Theo of 33333 shares of Kaleido Biosciences
Jerald Korn over a year ago via Macroaxis 
Acquisition by Jerald Korn of 45000 shares of Kaleido Biosciences subject to Rule 16b-3
Duke William E over a year ago via Macroaxis 
Acquisition by Duke William E of 50000 shares of Kaleido Biosciences subject to Rule 16b-3

Kaleido Biosciences Investors Sentiment

The influence of Kaleido Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kaleido. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KLDO

Kaleido Biosciences Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Kaleido Biosciences. What is your trading attitude regarding investing in Kaleido Biosciences? Are you bullish or bearish?
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.